Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx Pharmaceutical (NASDAQ: RARE) has announced the grant of 23,760 restricted stock units to 10 newly hired non-executive officers. The compensation committee approved these awards under the Ultragenyx Employment Inducement Plan, with a grant date of February 16, 2025. The grants, made in accordance with Nasdaq Listing Rule 5635(c)(4), serve as employment inducements for the new hires.
The restricted stock units have a four-year vesting schedule, with 25% of the shares vesting annually on the grant date anniversary, contingent on continuous employment.
Ultragenyx Pharmaceutical (NASDAQ: RARE) ha annunciato l'assegnazione di 23.760 unità azionarie ristrette a 10 nuovi dirigenti non esecutivi. Il comitato per la compensazione ha approvato questi premi nell'ambito del Piano di Induzione all'Occupazione di Ultragenyx, con una data di assegnazione fissata al 16 febbraio 2025. Le assegnazioni, effettuate in conformità con la Regola di Quotazione Nasdaq 5635(c)(4), fungono da incentivi all'occupazione per i nuovi assunti.
Le unità azionarie ristrette hanno un programma di maturazione di quattro anni, con il 25% delle azioni che maturano annualmente all'anniversario della data di assegnazione, a condizione di un impiego continuativo.
Ultragenyx Pharmaceutical (NASDAQ: RARE) ha anunciado la concesión de 23.760 unidades de acciones restringidas a 10 nuevos oficiales no ejecutivos. El comité de compensación aprobó estos premios bajo el Plan de Inducción al Empleo de Ultragenyx, con una fecha de concesión del 16 de febrero de 2025. Las concesiones, realizadas de acuerdo con la Regla de Cotización Nasdaq 5635(c)(4), sirven como incentivos de empleo para los nuevos contratados.
Las unidades de acciones restringidas tienen un programa de adquisición de cuatro años, con el 25% de las acciones que se adquieren anualmente en el aniversario de la fecha de concesión, condicionado a la continuidad del empleo.
Ultragenyx Pharmaceutical (NASDAQ: RARE)는 10명의 새로 고용된 비임원에게 23,760개의 제한 주식 단위를 부여한다고 발표했습니다. 보상 위원회는 2025년 2월 16일의 부여 날짜로 Ultragenyx 고용 유도 계획에 따라 이 상을 승인했습니다. 이 부여는 Nasdaq 상장 규칙 5635(c)(4)에 따라 이루어지며, 신규 채용에 대한 고용 유인으로 작용합니다.
제한 주식 단위는 4년의 베스팅 일정을 가지고 있으며, 25%의 주식이 부여 날짜의 기념일에 매년 베스팅되며, 지속적인 고용 조건이 필요합니다.
Ultragenyx Pharmaceutical (NASDAQ: RARE) a annoncé l'octroi de 23 760 unités d'actions restreintes à 10 nouveaux agents non exécutifs. Le comité de rémunération a approuvé ces récompenses dans le cadre du Plan d'Induction à l'Emploi d'Ultragenyx, avec une date d'octroi fixée au 16 février 2025. Les octrois, effectués conformément à la Règle de Cotation Nasdaq 5635(c)(4), servent d'incitations à l'emploi pour les nouvelles recrues.
Les unités d'actions restreintes ont un calendrier d'acquisition de quatre ans, avec 25 % des actions acquises chaque année à l'anniversaire de la date d'octroi, sous réserve d'un emploi continu.
Ultragenyx Pharmaceutical (NASDAQ: RARE) hat die Gewährung von 23.760 eingeschränkten Aktieneinheiten an 10 neu eingestellte nicht-executive Mitarbeiter bekannt gegeben. Der Vergütungsausschuss genehmigte diese Auszeichnungen im Rahmen des Ultragenyx Employment Inducement Plans mit einem Gewährungsdatum vom 16. Februar 2025. Die Gewährungen, die gemäß der Nasdaq-Listing-Regel 5635(c)(4) erfolgen, dienen als Beschäftigungsanreize für die neuen Mitarbeiter.
Die eingeschränkten Aktieneinheiten haben einen Vesting-Zeitplan von vier Jahren, wobei 25 % der Aktien jährlich am Jahrestag des Gewährungsdatums mit der Voraussetzung einer kontinuierlichen Beschäftigung vesten.
- Stock-based compensation aligns new employee interests with shareholders
- Potential shareholder dilution from 23,760 new restricted stock units
NOVATO, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 23,760 restricted stock units of the company’s common stock to 10 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of February 16, 2025, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).
The restricted stock units vest over four years, with
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.
Contact Ultragenyx
Investors & Media
Joshua Higa
(415) 475-6370
FAQ
How many restricted stock units did Ultragenyx (RARE) grant in February 2025?
What is the vesting schedule for Ultragenyx's (RARE) February 2025 restricted stock units?
How many new employees received Ultragenyx (RARE) restricted stock units in February 2025?
Under which rule were Ultragenyx's (RARE) February 2025 stock grants made?
